Milou S. van Driel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Milou S. van Driel has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Louis Vermeulen
Laboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC and University of Amsterdam, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands
5 shared publications - Sanne M. van Neerven
The Gurdon Institute, University of Cambridge, Cambridge, UK
5 shared publications Nina E. de Groot
Amsterdam UMC, location University of Amsterdam, Laboratory for Experimental Oncology and Radiobiology, van der Boechorststraat 6b, 1081BT, Amsterdam, The Netherlands
2 shared publicationsPrashanthi Ramesh
LEXOR, Center of Experimental Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
2 shared publicationsVaishali Kakkar
Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine Amsterdam UMC Location University of Amsterdam Amsterdam The Netherlands
2 shared publications- Arezo Torang
Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, 1081BT Amsterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
Apc truncation enforces optimal Wnt signalling during early intestinal tumourigenesis
Colorectal cancer (CRC) development is frequently initiated by inactivation of tumour suppressor gene adenomatous polyposis coli ( APC ), resulting in hyperactivation of the Wnt/ β-catenin signalling pathway. The level of Wnt pathway activation is determined by the number of functional β-catenin binding site repeats retained within the truncated APC protein. Accumulating evidence indicates that acquisition of the second APC mutational event is non-random and selects for mutations that confer a ‘just right’ level of Wnt activity, suggesting that tumour initiation requires Wnt signalling to be maintained within a specific range. In this study, we investigated how specific Apc mutations modulate Wnt pathway activity and downstream cellular programs. Using CRISPR/Cas9 technology, we generated mouse intestinal organoid cultures harbouring distinct alterations in the number of β-catenin binding repeats. We demonstrate a direct correlation between the number of retained repeats and Wnt signalling activity. Notably, organoids retaining higher numbers of functional repeats were subjected to selective pressure, resulting in the acquisition of additional mutations that lead to increased Wnt activity, consistent with the ‘just right’ model. Transcriptomic analysis by RNA sequencing revealed that clones with distinct β-catenin binding capacity exhibit differential transcriptional programs, including graded changes in cell cycle activity and a metabolic shift associated with progressive loss of β-catenin binding repeats. Together, these findings reveal functional and metabolic heterogeneity among Apc- mutant cells, support the existence of selective pressures for optimal Wnt signalling during tumor initiation, and identify potential metabolic vulnerabilities that may be exploited for therapeutic intervention including interception of premalignant lesions.
Open AccessApc truncation enforces optimal Wnt signalling during early intestinal tumourigenesis
Colorectal cancer (CRC) development is frequently initiated by inactivation of tumour suppressor gene adenomatous polyposis coli ( APC ), resulting in hyperactivation of the Wnt/ β-catenin signalling pathway. The level of Wnt pathway activation is determined by the number of functional β-catenin binding site repeats retained within the truncated APC protein. Accumulating evidence indicates that acquisition of the second APC mutational event is non-random and selects for mutations that confer a ‘just right’ level of Wnt activity, suggesting that tumour initiation requires Wnt signalling to be maintained within a specific range. In this study, we investigated how specific Apc mutations modulate Wnt pathway activity and downstream cellular programs. Using CRISPR/Cas9 technology, we generated mouse intestinal organoid cultures harbouring distinct alterations in the number of β-catenin binding repeats. We demonstrate a direct correlation between the number of retained repeats and Wnt signalling activity. Notably, organoids retaining higher numbers of functional repeats were subjected to selective pressure, resulting in the acquisition of additional mutations that lead to increased Wnt activity, consistent with the ‘just right’ model. Transcriptomic analysis by RNA sequencing revealed that clones with distinct β-catenin binding capacity exhibit differential transcriptional programs, including graded changes in cell cycle activity and a metabolic shift associated with progressive loss of β-catenin binding repeats. Together, these findings reveal functional and metabolic heterogeneity among Apc- mutant cells, support the existence of selective pressures for optimal Wnt signalling during tumor initiation, and identify potential metabolic vulnerabilities that may be exploited for therapeutic intervention including interception of premalignant lesions.
- Open Access
- 13 July 2025
- Published by Springer Nature in Oncogenesis
- Vol. 14 (1) , 1-8
GSK-3 and BCL-XL inhibition mitigates the competitive advantage of APC-mutant colorectal cancer cells
BCL-XL is a crucial anti-apoptotic protein that supports survival of intestinal cells during the progression and in established colorectal cancer (CRC). While targeting BCL-XL with BH3 mimetics is effective, its significant toxicity highlights the need for alternative approaches. Importantly, the early steps in intestinal transformation are marked by a competition between normal and transformed stem cells in which the mutant cells gain a supercompetitive advantage due to the secretion of WNT inhibitors. Using multiple human and murine CRC models, we revealed that GSK-3 inhibition strongly sensitized to BH3 mimetic-induced killing. As expected, GSK-3 inhibition significantly upregulated the WNT pathway, but also led to marked enhancement of BH3 mimetic-induced apoptosis, as measured by mitochondrial BAX aggregation, Caspase-3 activation and Propidium Iodide exclusion. Furthermore, GSK-3 inhibition provided an advantage to wild-type intestinal organoids in competition with APC-mutant counterparts due to reactivation of the WNT pathway. More strikingly, combining GSK-3 and BCL-XL inhibition profoundly affected the supercompetition APC-mutant intestinal cells exert over the wild-types. In effect, the combination therapy enhanced the competitive fitness of wild-type cells and resulted in the killing of APC-mutant organoids, pointing to a novel combination therapy that can be further exploited in the treatment of adenomas and CRC.
- 13 July 2025
- Published by Springer Nature in Oncogenesis
- Vol. 14 (1) , 1-8
Open AccessGSK-3 and BCL-XL inhibition mitigates the competitive advantage of APC-mutant colorectal cancer cells
BCL-XL is a crucial anti-apoptotic protein that supports survival of intestinal cells during the progression and in established colorectal cancer (CRC). While targeting BCL-XL with BH3 mimetics is effective, its significant toxicity highlights the need for alternative approaches. Importantly, the early steps in intestinal transformation are marked by a competition between normal and transformed stem cells in which the mutant cells gain a supercompetitive advantage due to the secretion of WNT inhibitors. Using multiple human and murine CRC models, we revealed that GSK-3 inhibition strongly sensitized to BH3 mimetic-induced killing. As expected, GSK-3 inhibition significantly upregulated the WNT pathway, but also led to marked enhancement of BH3 mimetic-induced apoptosis, as measured by mitochondrial BAX aggregation, Caspase-3 activation and Propidium Iodide exclusion. Furthermore, GSK-3 inhibition provided an advantage to wild-type intestinal organoids in competition with APC-mutant counterparts due to reactivation of the WNT pathway. More strikingly, combining GSK-3 and BCL-XL inhibition profoundly affected the supercompetition APC-mutant intestinal cells exert over the wild-types. In effect, the combination therapy enhanced the competitive fitness of wild-type cells and resulted in the killing of APC-mutant organoids, pointing to a novel combination therapy that can be further exploited in the treatment of adenomas and CRC.
- Open Access
Pleiotropic role of NOTUM in colorectal cancer
- Open Access
- 2 November 2022
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (12) , e16194
Intestinal Apc‐inactivation induces HSP25 dependency
The majority of colorectal cancers (CRCs) present with early mutations in tumor suppressor gene APC. APC mutations result in oncogenic activation of the Wnt pathway, which is associated with hyperproliferation, cytoskeletal remodeling, and a global increase in mRNA translation. To compensate for the increased biosynthetic demand, cancer cells critically depend on protein chaperones to maintain proteostasis, although their function in CRC remains largely unexplored. In order to investigate the role of molecular chaperones in driving CRC initiation, we captured the transcriptomic profiles of murine wild type and Apc‐mutant organoids during active transformation. We discovered a strong transcriptional upregulation of Hspb1, which encodes small heat shock protein 25 (HSP25). We reveal an indispensable role for HSP25 in facilitating Apc‐driven transformation, using both in vitro organoid cultures and mouse models, and demonstrate that chemical inhibition of HSP25 using brivudine reduces the development of premalignant adenomas. These findings uncover a hitherto unknown vulnerability in intestinal transformation that could be exploited for the development of chemopreventive strategies in high‐risk individuals.
- 2 November 2022
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (12) , e16194
Open AccessIntestinal Apc‐inactivation induces HSP25 dependency
The majority of colorectal cancers (CRCs) present with early mutations in tumor suppressor gene APC. APC mutations result in oncogenic activation of the Wnt pathway, which is associated with hyperproliferation, cytoskeletal remodeling, and a global increase in mRNA translation. To compensate for the increased biosynthetic demand, cancer cells critically depend on protein chaperones to maintain proteostasis, although their function in CRC remains largely unexplored. In order to investigate the role of molecular chaperones in driving CRC initiation, we captured the transcriptomic profiles of murine wild type and Apc‐mutant organoids during active transformation. We discovered a strong transcriptional upregulation of Hspb1, which encodes small heat shock protein 25 (HSP25). We reveal an indispensable role for HSP25 in facilitating Apc‐driven transformation, using both in vitro organoid cultures and mouse models, and demonstrate that chemical inhibition of HSP25 using brivudine reduces the development of premalignant adenomas. These findings uncover a hitherto unknown vulnerability in intestinal transformation that could be exploited for the development of chemopreventive strategies in high‐risk individuals.
- Open Access
- 16 December 2021
- Published by Elsevier in STAR Protocols
- Vol. 3 (1) , 101050
Intestinal organoid co-culture protocol to study cell competition in vitro
- 16 December 2021
- Published by Elsevier in STAR Protocols
- Vol. 3 (1) , 101050
Open AccessIntestinal organoid co-culture protocol to study cell competition in vitro
- Top Cited Papers
- 2 June 2021
- Published by Springer Nature in Nature
- Vol. 594 (7863) , 436-441
Apc-mutant cells act as supercompetitors in intestinal tumour initiation
A delicate equilibrium of WNT agonists and antagonists in the intestinal stem cell (ISC) niche is critical to maintaining the ISC compartment, as it accommodates the rapid renewal of the gut lining. Disruption of this balance by mutations in the tumour suppressor gene APC, which are found in approximately 80% of all human colon cancers, leads to unrestrained activation of the WNT pathway1,2. It has previously been established that Apc-mutant cells have a competitive advantage over wild-type ISCs3. Consequently, Apc-mutant ISCs frequently outcompete all wild-type stem cells within a crypt, thereby reaching clonal fixation in the tissue and initiating cancer formation. However, whether the increased relative fitness of Apc-mutant ISCs involves only cell-intrinsic features or whether Apc mutants are actively involved in the elimination of their wild-type neighbours remains unresolved. Here we show that Apc-mutant ISCs function as bona fide supercompetitors by secreting WNT antagonists, thereby inducing differentiation of neighbouring wild-type ISCs. Lithium chloride prevented the expansion of Apc-mutant clones and the formation of adenomas by rendering wild-type ISCs insensitive to WNT antagonists through downstream activation of WNT by inhibition of GSK3β. Our work suggests that boosting the fitness of healthy cells to limit the expansion of pre-malignant clones may be a powerful strategy to limit the formation of cancers in high-risk individuals.
- 2 June 2021
- Published by Springer Nature in Nature
- Vol. 594 (7863) , 436-441
Top Cited PapersApc-mutant cells act as supercompetitors in intestinal tumour initiation
A delicate equilibrium of WNT agonists and antagonists in the intestinal stem cell (ISC) niche is critical to maintaining the ISC compartment, as it accommodates the rapid renewal of the gut lining. Disruption of this balance by mutations in the tumour suppressor gene APC, which are found in approximately 80% of all human colon cancers, leads to unrestrained activation of the WNT pathway1,2. It has previously been established that Apc-mutant cells have a competitive advantage over wild-type ISCs3. Consequently, Apc-mutant ISCs frequently outcompete all wild-type stem cells within a crypt, thereby reaching clonal fixation in the tissue and initiating cancer formation. However, whether the increased relative fitness of Apc-mutant ISCs involves only cell-intrinsic features or whether Apc mutants are actively involved in the elimination of their wild-type neighbours remains unresolved. Here we show that Apc-mutant ISCs function as bona fide supercompetitors by secreting WNT antagonists, thereby inducing differentiation of neighbouring wild-type ISCs. Lithium chloride prevented the expansion of Apc-mutant clones and the formation of adenomas by rendering wild-type ISCs insensitive to WNT antagonists through downstream activation of WNT by inhibition of GSK3β. Our work suggests that boosting the fitness of healthy cells to limit the expansion of pre-malignant clones may be a powerful strategy to limit the formation of cancers in high-risk individuals.